Stocks and Investing Stocks and Investing
Fri, March 27, 2020

David Lewis Maintained (ABT) at Buy with Decreased Target to $96 on, Mar 27th, 2020


Published on 2024-10-27 01:11:25 - WOPRAI, David Lewis
  Print publication without navigation


David Lewis of Morgan Stanley, Maintained "Abbott Laboratories" (ABT) at Buy with Decreased Target from $101 to $96 on, Mar 27th, 2020.

David has made no other calls on ABT in the last 4 months.



There are 10 other peers that have a rating on ABT. Out of the 10 peers that are also analyzing ABT, 4 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Amit Hazan of "Goldman Sachs" Initiated at Hold and Held Target at $96 on, Thursday, February 13th, 2020
  • Marie Thibault of "BTIG" Initiated at Hold on, Thursday, February 6th, 2020
  • Danielle Antalffy of "SVB Leerink" Maintained at Hold with Increased Target to $102 on, Thursday, January 23rd, 2020
  • Christopher Pasquale of "Guggenheim" Downgraded from Strong Buy to Hold on, Thursday, January 2nd, 2020


These are the ratings of the 6 analyists that currently disagree with David


  • Matt Miksic of "Credit Suisse" Maintained at Buy with Decreased Target to $94 on, Friday, March 6th, 2020
  • Joanna Wiensch of "Citigroup" Initiated at Strong Buy and Held Target at $96 on, Thursday, March 5th, 2020
  • Larry Biegelsen of "Wells Fargo" Maintained at Buy with Increased Target to $103 on, Thursday, January 23rd, 2020
  • Jayson Bedford of "Raymond James" Maintained at Buy with Increased Target to $99 on, Thursday, January 23rd, 2020
  • Matthew Taylor of "UBS" Maintained at Strong Buy with Increased Target to $105 on, Thursday, January 23rd, 2020
  • Rick Wise of "Stifel" Maintained at Strong Buy with Increased Target to $104 on, Thursday, January 23rd, 2020
Contributing Sources